June 2, 2020 -- Contract development and manufacturing organization AGC Biologics has purchased a large-scale biopharmaceutical manufacturing facility in Boulder, CO.
The automated facility was previously owned by AstraZeneca and is well designed for high-volume commercial production, AGC noted. It contains two 20,000-liter stainless steel mammalian cell bioreactors with room for four additional bioreactors and has more than twenty acres for future expansion.
AGC plants to run full-scale operations at the new facility by April 2021. It will help the company advance a higher ratio of late-phase and commercial products and support a wider range of commercial demand, the company noted.
In addition, AGC will complete facility expansion projects in Seattle, Denmark, and Japan this year and in early 2021.